<?xml version="1.0" encoding="UTF-8"?>
<p id="p0175">RIB has become a go-to drug in antiviral therapy, especially when looking to target the replication of viruses with few options for treatment. At one time, RIB was the major treatment for Hepatitis C Virus infection but now RIB-independent therapies have become commonplace in the clinic (
 <xref rid="bib18" ref-type="bibr">Kish et al., 2017</xref>). RIB remains the first line of antiviral therapy against other viruses on the world stage, including MERS-CoV (Middle East Respiratory Syndrome-Corona Virus), Lassa Fever Virus, and Zika virus (
 <xref rid="bib17" ref-type="bibr">Kamiyama et al., 2017</xref>; 
 <xref rid="bib6" ref-type="bibr">Carrillo-Bustamante et al., 2017</xref>; 
 <xref rid="bib7" ref-type="bibr">Chong et al., 2015</xref>). However, a different mechanism of action may be at work for every virus that RIB effectively treats, including nucleoside base level changes and catastrophic error induction in cells (
 <xref rid="bib33" ref-type="bibr">Te et al., 2007</xref>; 
 <xref rid="bib9" ref-type="bibr">Crotty et al., 2002</xref>).
</p>
